$GNVR

Genvor Inc

CIK:0001792941|SEC Filings

Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
REVENUE
OPERATING EXPENSES:
Research and development expenses	205,977	271,816	320,352	390,052
Advertising and marketing expenses	15,281		42,073	3,758
Professional fees	481,851	80,356	728,811	100,436
Compensation and related benefits	1,516,403	184,824	2,042,749	5,283,418
Other General and Administrative Expense	261,501	40,547	317,175	73,349
Total Operating Expenses	2,481,013	577,543	3,451,160	5,851,013
LOSS FROM OPERATIONS	(2,481,013)	(577,543)	(3,451,160)	(5,851,013)
OTHER INCOME (EXPENSES)
Interest expense	(61,703)	(16,138)	(91,046)	(42,902)
Gain (loss) on settlement of accounts payable, net		8,902	(6,357)	8,902
Gain on settlement of note payable		187,000		187,000
Change in fair value of warrant liabilities	(13,752)		(13,752)
Total Other Income (Expenses), net	(75,455)	179,764	(111,155)	153,000
LOSS BEFORE INCOME TAXES	(2,556,468)	(397,779)	(3,562,315)	(5,698,013)
INCOME TAXES
NET LOSS	$ (2,556,468)	$ (397,779)	$ (3,562,315)	$ (5,698,013)
NET LOSS PER COMMON SHARE:
Earnings Per Share, Basic	$ (0.07)	$ (0.01)	$ (0.1)	$ (0.23)
Earnings Per Share, Diluted	$ (0.07)	$ (0.01)	$ (0.1)	$ (0.23)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Weighted Average Number Of Shares Outstanding Basic	36,083,168	27,471,752	34,654,540	24,331,752
Weighted Average Number Of Shares Outstanding Diluted	36,083,168	27,471,752	34,654,540	24,331,752

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (3,562,315)	$ (5,698,013)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		1,375
Stock-based compensation and service expense	346,700	4,862,500
Loss (gain) on settlement of accounts payable	22,257	(8,902)
Gain on settlement of note payable		(187,000)
Amortization of debt discount	45,801	9,999
Series C Preferred Stock issued for services	381,641
Common stock issued for services	129,153
Change in fair value of warrant liabilities	13,752
Changes in assets and liabilities:
Prepaid expense	(11,986)	16,344
Accrued interest - convertible notes payable	5,834	32,888
Accrued interest - related parties	37,616
Accounts payable and accrued expenses	(67,897)	(57,650)
Accrued compensation	114,000	628,520
Tax reimbursement policy liabilities	1,646,487
Net cash used in operating activities	(898,957)	(399,939)
Cash flows from financing activities:
Payment of deferred offering costs	(50,000)
Proceeds from convertible notes payable, net	470,000
Payments on financed payable	(27,085)
Advances from related parties		86,995
Repayments to related parties		(18,996)
Proceeds from sale of common stock and pre-funded warrants	665,333	430,000
Proceeds from common stock warrant exercises		500
Net cash provided by financing activities	1,058,248	498,499
Net increase in cash	159,291	98,560
Cash at beginning of period	37,231	373
Cash at end of period	196,522	98,933
Supplemental cash flow information
Cash paid for interest
Cash paid for taxes
Non-cash investing and financing activities:
Accrued compensation settled with common stock	411,000
Conversion of note payable and accrued interest to shares of common stock	22,092	217,000
Accrued liabilities settled with shares of common stock	126,250
Cancellation of shares of common stock due to legal settlement and other settlements	331
Conversion of series B preferred stock to shares of common stock	150
Shares of common stock issued for warrant exercises	1,440
Prepaid insurance premium and financing liability	45,144
Accounts payable settled with shares of common stock	55,955
Warrant liabilities issued with convertible notes payable	$ 198,612

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Sep. 30, 2025
CURRENT ASSETS:
Cash	$ 196,522	$ 37,231
Prepaid expense	65,721	8,591
Total Current Assets	262,243	45,822
NON-CURRENT ASSETS:
Deferred offering costs	50,000
Total Assets	312,243	45,822
CURRENT LIABILITIES:
Convertible notes payable, net of unamortized discount	317,189	20,000
Financed payable	18,059
Accrued interest on convertible notes payable	5,834	2,211
Accrued interest - related parties	92,431	54,815
Accounts payable and accrued expenses	116,916	366,899
Accrued compensation and related expenses	484,392	781,392
Tax reimbursement policy liabilities (Note 8)	1,646,487
SBA loan	48,750	48,750
Total Current Liabilities	2,814,195	1,358,204
NON-CURRENT LIABILITIES:
Warrant liabilities	212,364
Total Liabilities	3,026,559	1,358,204
Commitments and Contingencies (Note 8)
STOCKHOLDERS’ DEFICIT:
Preferred stock, value
Common stock, $0.001 par value; 300,000,000 shares authorized; 36,675,786 and 30,175,763 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively	36,410	30,175
Common stock to be issued, $0.001 par value; 265,666 and 0 shares to be issued at June 30, 2026 and September 30, 2025, respectively	266
Additional paid-in capital	27,302,718	25,148,688
Less: series B preferred stock held in treasury, at cost; 502,512 shares at June 30, 2026 and September 30, 2025, respectively	(300,000)	(300,000)
Accumulated deficit	(29,755,621)	(26,193,306)
Total Stockholders' Deficit	(2,714,316)	(1,312,382)
Total Liabilities and Stockholders' Deficit	312,243	45,822
Related Party
CURRENT LIABILITIES:
Advances from related parties	84,137	84,137
Series B Preferred Stock
STOCKHOLDERS’ DEFICIT:
Preferred stock, value	1,911	2,061
Series C Preferred Stock
STOCKHOLDERS’ DEFICIT:
Preferred stock, value